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Summary
Von Willebrand disease (VWD) is the most common inher-
ited bleeding disorder. Most patients with mild and moderate
VWD can be treated effectively with desmopressin. The man-
agement of severe VWD patients, mostly affected by type 2
and type 3 disease, can be challenging. In this article we
review the current diagnosis and treatment of severe VWD
patients. We will also discuss the management of severe
VWD patients in specific situations, such as pregnancy, deliv-
ery, patients developing alloantibodies against von Wille-
brand factor and VWD patients with recurrent
gastrointestinal bleeding. Moreover, we review emerging
treatments that may be applied in future management of
patients with severe VWD.
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Von Willebrand disease (VWD) is the most common inher-
ited bleeding disorder (Leebeek & Eikenboom, 2016). The
estimated prevalence of VWD patients with clinically relevant
bleeding is 1:10 000 (Sadler et al, 2000). VWD is character-
ized by mucocutaneous bleeding such as menorrhagia, epis-
taxis and gum bleeds (de Wee et al, 2012; Leebeek &
Eikenboom, 2016). However, other bleeds, such as joint
bleeds and gastro-intestinal bleeds, also occur, especially in
more severely affected patients (van Galen et al, 2017). VWD
diagnosis is based on personal bleeding history, family his-
tory of VWD and a detailed laboratory evaluation (Leebeek
& Eikenboom, 2016).
Von Willebrand disease is classified in three subtypes
based on a quantitative reduction or a qualitative defect of
von Willebrand factor (VWF) (Sadler et al, 2006; Leebeek &
Eikenboom, 2016). Type 1 VWD is characterized by a quan-
titative reduction of VWF, and is the most common (70–
80%) form of VWD. The bleeding phenotype of type 1
VWD patients is generally milder than in type 2 and type 3
VWD (de Wee et al, 2012). Type 2 VWD is diagnosed in
20% of VWD patients and is characterized by a qualitative
defect of VWF, and the bleeding phenotype is generally more
severe than in type 1 VWD patients. Type 3 VWD is the rar-
est (prevalence <5%) and most severe form of VWD; it is
characterized by a complete absence of VWF (Leebeek &
Eikenboom, 2016).
The VWF gene, which largely determines VWF levels in
circulation, is located at chromosome 12. A large variation of
mutations or deletions in the VWF gene are associated with
VWD (de Jong & Eikenboom, 2017). The inheritance pattern
of VWD is autosomal dominant in the majority of cases
(Leebeek & Eikenboom, 2016). In type 1 VWD, most
patients have autosomal dominant missense mutations with
an incomplete penetrance and a variable expression (Leebeek
& Eikenboom, 2016). In type 2 VWD, dominant negative
missense mutations of specific VWF gene regions lead to an
abnormally functioning VWF. The location of the VWF
mutation determines the abnormal VWF function and, sub-
sequently, the subtype of type 2 VWD (de Jong & Eiken-
boom, 2017). In type 3 VWD, up to 80% of patients have a
null allele mutation, which is autosomal recessive and
homozygous, or compound heterozygous in most patients
(Leebeek & Eikenboom, 2016).
Severe VWD
Unlike in haemophilia, in which the severity of disease is
based on factor VIII (FVIII) or factor IX (FIX) levels, there
is no uniformly accepted definition for mild, moderate or
severe VWD. VWD diagnosis relies on criteria defined by
Sadler et al (2006), although that classification did not define
severe or moderate VWD.
Federici (2004) classified patients with VWF: Ristocetin
cofactor activity (VWF:RCo) levels <10 iu/dl and FVIII coag-
ulant activity (FVIII:C) <20 iu/dl as severe (mainly type 1,
2A, 2B and 3); VWF:RCo 10–30 iu/dl and FVIII:C 20–40 iu/
dl (mainly type 1, 2B, 2M and 2N) as moderate and VWF:
RCo 30–50 iu/dl and FVIII:C 40–60 iu/dl (mainly type 1) as
mild VWD. More recently, it has been suggested that
patients with bleeding symptoms and VWF levels between
30–50 iu/dl should not be classified as mild VWD, but as
“low VWF” (Leebeek & Eikenboom, 2016; Lavin et al, 2017).
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In more recently published and ongoing studies on the use
of prophylaxis in VWD, severe VWD was defined as VWF:
RCo < 20 iu/dl (Abshire et al, 2015). However, the most
widely used definition of severe VWD is based on VWF
activity levels <10 iu/dl and/or FVIII levels <20 iu/dl. Thus,
this includes type 3 VWD patients with a complete absence
of VWF and most type 2B VWD patients, who generally also
have a severe bleeding phenotype (de Wee et al, 2012). Also
patients with type 2A and Type 1 Vicenza, which is charac-
terized by a fast clearance of VWF, fulfil the definition of
severe VWD (Leebeek & Eikenboom, 2016). It should be
acknowledged that these definitions are not uniformly used
and guidelines from Europe or USA may differ on cut-off
values for the diagnosis of VWD and definition of severe
VWD (Nichols et al, 2008; Castaman et al, 2013; Laffan et al,
2014).
Therefore, this guideline is intended for a broad range of
severe VWD patients with type 1 Vicenza, type 1 with VWF
levels <10 iu/dl, type 2A, type 2B and type 3 disease. It is
also intended for other individual VWD patients with a sev-
ere bleeding phenotype irrespective of their disease type.
Additionally, we include recommendations for patients with
a high risk for bleeding in specific situations, such as preg-
nant women with VWD in whom VWF levels do not
increase above 50 iu/dl during third trimester, and patients
with recurrent gastrointestinal bleeding.
Diagnosis of severe VWD
Von Willebrand disease is characterized by defective platelet
adhesion and aggregation. As VWF is a carrier protein for
FVIII, thereby preventing FVIII degradation, patients with
severe VWD also have reduced FVIII levels. FVIII levels are
strongly reduced, particularly in patients with type 3 VWD
(Sanders et al, 2015). The laboratory evaluation of an indi-
vidual with a bleeding phenotype suggestive of VWD,
includes measurement of VWF antigen (VWF:Ag), VWF
activity [VWF:RCo and VWF: collagen binding activity
(VWF:CB)], VWF multimer pattern and FVIII:C (Ng et al,
2015; De Jong & Eikenboom, 2016). The discussion about
the cut-off value of VWF to diagnose VWD is still not com-
pletely resolved. According to the European principles of care
for VWD, the value was defined as 40 iu/dl whereas others
defined VWD based on VWF:Ag or VWF:RCo below 30 iu/
dl, which is now also used in most recent guidelines (Nichols
et al, 2008; Castaman et al, 2013; Laffan et al, 2014; Leebeek
& Eikenboom, 2016).
Type 1 VWD is diagnosed when the VWF:RCo/VWF:Ag
ratio is >06. Type 2 VWD is diagnosed based on an abnor-
mal function of VWF (VWF:RCo/VWF:Ag ratio ≤06). Type
2 VWD is further subdivided in type 2A, 2B, 2M and 2N
(Sadler et al, 2006). Type 2A and type 2B VWD are charac-
terized by a loss of high molecular weight (HMW) multi-
mers, which are the most active haemostatic multimers. Loss
of HMW multimers lead to a moderate to severe bleeding
phenotype. The typical gain of function mutations causing
type 2B VWD lead to a higher affinity to bind the platelet
glycoprotein (GP)1ba receptor, and subsequently leads to
increased platelet binding and aggregation (Leebeek & Eiken-
boom, 2016). Therefore, type 2A and type 2B VWD patients
can be distinguished from each other using the ristocetin-in-
duced platelet adhesion (RIPA) test, which is positive with
low concentrations of ristocetin in type 2B VWD. Type 2M
VWD is characterized by a decreased platelet adhesion or
collagen binding, without loss of HMW VWF multimers.
Type 2N VWD is caused by a missense mutation in the D’-
D3 domain of the VWF gene, leading to decreased VWF-
FVIII binding (Leebeek & Eikenboom, 2016). These patients
have generally low FVIII compared to VWF levels. Based on
the most recent International Society on Thrombosis and
Haemostasis (ISTH) classification, type 3 VWD is defined as
undetectable VWF levels (VWF:Ag ≤ 5 iu/dl) (Sadler et al,
2006). However, this definition will include also patients with
severe type 1 VWD. Therefore, it has recently been proposed
that type 3 VWD would be more precisely diagnosed by
assessing VWF propeptide (VWFpp) levels and defining only
those individuals with VWFpp levels ≤5 iu/dl as type 3 VWD
(Sanders et al, 2015).
Several diagnostic tests have been developed to assess the
functionality of VWF. The most widely used test is the VWF:
RCo test. Due to the fact that the originally developed assay
is elaborate and time consuming, has a poor sensitivity and
high variation, several new activity tests have been developed
in recent years (Bodo et al, 2015; Boender et al, 2018). In a
recent study, the four currently most widely used VWF activ-
ity assays were compared in a cohort of 661 well-defined
VWD patients (Boender et al, 2018). The assays were found
to be highly correlated with each other. However, in some
patients, discrepancies in VWF activity assays resulted in a
different classification of the type of VWD. The VWF:RCo
assay, using ristocetin to activate VWF and whole platelets,
was not sensitive enough to classify 18% of the total study
population and misclassified half of the genotypically identi-
fied 2B patients. Also the VWF:GPIbM test, using gain-of-
function GPIb fragments that bind spontaneously to VWF,
misclassified some definite type 2 and type 3 VWD patients
(Boender et al, 2018).
Our institution’s VWD diagnostic algorithm is based on
recently published reviews on VWD (Ng et al, 2015; De Jong
& Eikenboom, 2016; Leebeek & Eikenboom, 2016). In our
laboratory we measure FVIII:C, VWF:Ag (in-house assay),
the automated VWF:GPIbM assay and VWF:CB assay to test
the VWF activity, followed by multimer analysis and, in case
of reduced HMW multimers, also the RIPA assay. In case of
low FVIII we perform a FVIII: binding to VWF test to diag-
nose or exclude type 2N.
Genetic testing may be considered in patients with severe
VWD. Genetic counselling may be required in families with
type 3 disease: for instance, in cases where a couple already
has a child with type 3 disease (Peake & Goodeve, 2010).
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Mutation analysis of both parents is necessary to identify the
causative mutations and thereby enable an early diagnosis
with chorionic villus sampling. In nearly all type 2 VWD
patients a mutation in the VWF gene is found, but the clini-
cal use of knowing the mutation in daily practice is debat-
able. Many patients with severe type 1 disease also have
mutations, but this is strongly dependent upon the level of
VWF (Leebeek & Eikenboom, 2016). The yield of genetic
testing is over 90% in individuals with VWF levels <15 iu/dl,
but in individuals with levels between 16 to 30 iu/dl it is
only around 75% (Goodeve et al, 2007).
In our centre we do not routinely perform mutation anal-
ysis in VWD, unless it has clinical implications. Indications
for performing mutation analysis are counselling for family
planning in type 3, and diagnosing type 2B. We also perform
mutation analysis in VWD type 2 patients, to enable the
diagnosis of, or exclude, VWD in their unborn child by
amniotic fluid sampling at 32–34 weeks of pregnancy and to
assess whether an atraumatic delivery is necessary. We also
perform genetic testing for scientific purposes, for instance in
the Willebrand in the Netherlands (WiN) study (Boender
et al, 2018).
Bleeding phenotype of severe VWD
von Willebrand disease is characterized mainly by mucocuta-
neous bleeding symptoms, including menorrhagia, nose
bleeds, easy bruising and gastro-intestinal bleeding (de Wee
et al, 2012). In contrast to haemophilia patients, in whom
factor levels are well associated with the severity of the bleed-
ing phenotype, this is less clear in VWD. The bleeding phe-
notype of VWD is highly heterogeneous. Even patients with
the same type of VWD and comparable levels of VWF activ-
ity can have a variable bleeding phenotype (de Wee et al,
2012; Flood et al, 2016).
In severe VWD the bleeding phenotype is clearly different
from milder forms, mainly because of the co-existing
strongly reduced FVIII:C levels (Leebeek & Eikenboom,
2016). This was also observed in the WiN study, in which
40% of the included patients with VWD had severe VWD
based on VWF levels (antigen or activity) <10 iu/dl (de Wee
et al, 2012). Metjian et al (2009) reported the bleeding phe-
notype in 150 VWD patients with VWF levels <10 u/dl.
Almost all patients experienced bleeding episodes and >90%
of patients had been treated with factor concentrates. Joint
and muscle bleeds had occurred in 45% and 28% of patients,
respectively. Also in the WiN-study, 58% of patients with
type 3 disease reported joint bleeds, for which they received
haemostatic treatment, whereas only 12% of patients with
type 2 reported joint bleeds (van Galen et al, 2015). Joint
bleeds in VWD patients may also result in arthropathy, as is
observed in patients with haemophilia. In a recent study of
49 VWD patients with a verified history of joint bleeds,
arthropathy was observed in 40% of the cases (van Galen
et al, 2017). This was associated with more pain, functional
limitations and less social participation compared to control
VWD patients without joint bleeds. These patients had com-
parable outcomes to moderate severe haemophilia A patients
(van Galen et al, 2018).
Type 2 VWD patients are a heterogeneous group and
bleeding severity may differ between the various subtypes.
Patients with type 2B have a more severe bleeding phenotype
compared to other type 2 patients, due to the lack of HMW
multimers and thrombocytopenia (Federici et al, 2009; de
Wee et al, 2012). A prospective study showed that patients
with type 2A had a more severe bleeding phenotype than
patients with type 2M, which was mainly due to more gas-
tro-intestinal bleeding in the 2A patients. Because this was
not related to FVIII or VWF levels, it is suggested that this
was also due to the lack of HMW multimers in type 2A
(Castaman et al, 2012).
In recent years, bleeding scores have been used to assess
the severity of the bleeding phenotype. This was originally
developed to improve the diagnosis of patients suffering
from a bleeding tendency who were referred to specialized
haematology clinics (Tosetto et al, 2006; Rodeghiero et al,
2007; Tosetto et al, 2008). By obtaining a well-structured
bleeding history on 13 items and scoring those items for
severity of bleeding, a total bleeding score can be obtained.
Several scores have been developed over the last years (Rydz
& James, 2012). The ISTH Bleeding Assessment Tool (ISTH-
BAT) is currently the most widely used score (Rydz & James,
2012) and is helpful in diagnosing bleeding disorders, includ-
ing VWD. Patients with a normal ISTH BAT score have a
very low risk of having an inherited bleeding disorder. How-
ever, this may depend on age and on the haemostatic chal-
lenges that an individual has encountered. Bleeding scores
have also been used to study the severity of the bleeding ten-
dency in individuals previously diagnosed with VWD.
Despite the fact that the bleeding symptoms may strongly
vary between individuals, patients with severe VWD, includ-
ing types 2 and 3, have clearly higher scores than type 1
patients (de Wee et al, 2012).
Federici et al (2014) investigated whether the bleeding
score can be used to predict future bleeding and clinical out-
comes in VWD patients (Federici et al, 2014). In a prospec-
tive study, VWF:RCo of <10 iu/dl and a high bleeding score
(>10) were associated with an increased risk of developing a
bleeding episode in the year to come. A bleeding score >10
remained highly associated with bleeding that needed haemo-
static treatment after multivariate analysis. This may also be
useful to identify severe VWD patients in need of intensive
treatment before surgery or other interventions, and may also
identify patients who may benefit from long term prophy-
laxis with FVIII/VWF concentrate (Federici et al, 2014).
An increased burden of bleeding symptoms and the bleed-
ing score are strongly associated with a reduced health-re-
lated quality of life (HRQoL) both in children and adults
with VWD (de Wee et al, 2010; de Wee et al, 2011a). A
more severe bleeding phenotype was associated with lower
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scores on the domains of physical functioning, bodily pain
and general health (Atiq et al, 2019, de Wee et al, 2011a,
2011b). Type 3 VWD patients had a lower HRQoL compared
to types 1 and 2. Bleeding scores were also strongly associ-
ated with HRQoL. Given that chronic pain, mainly related to
joint bleeds, and arthropathy are strongly related to physical
and mental health, efforts should be made to prevent and
manage these bleeding episodes (McLaughlin et al, 2017).
Treatment of severe VWD patients
Severe VWD patients should be treated in specialised centres
that have experience with the management of bleeding disor-
ders, especially when patients are in need of treatment with
factor concentrates. FVIII/VWF concentrates should be read-
ily available and these centres should have a haemostasis lab-
oratory with the ability to measure VWF and/or FVIII levels
immediately (Castaman et al, 2013).
The goal of treatment in VWD patients is to primarily
improve platelet adhesion and aggregation by increasing
VWF and, secondly, to improve fibrin formation by increas-
ing FVIII levels in the circulation (Heijdra et al, 2017). This
can be achieved by stimulating endogenous VWF and FVIII
release from Weibel-Palade Bodies by desmopressin, or infu-
sion of exogenous VWF with or without FVIII, (Castaman
et al, 2013; Leebeek & Eikenboom, 2016). Based on these
approaches, several treatment options are currently available.
Desmopressin
The most used treatment option to increase VWF and FVIII
levels in patients with mild or moderate VWD is to adminis-
ter desmopressin (1-deamino-8-d-arginine vasopressin,
DDAVP) (Heijdra et al, 2017). Desmopressin stimulates
endogenous VWF release from the endothelium into the cir-
culation. Unfortunately type 3 patients are unresponsive due
to the lack of endogenous VWF and only a limited number
of severe type 1 and type 2 VWD patients can be treated
with desmopressin (Leebeek & Eikenboom, 2016).
In a large study on severe VWD patients with VWF levels
below 10 iu/dl at the time of desmopressin administration,
in which response to desmopressin was defined as increase of
plasma FVIII:C and VWF:RCo of at least 3-fold over base-
line, levels of at least 30 iu/dl, and a bleeding time of 12 min
or less 2 h after the end of desmopressin infusion, most type
1 patients did not respond (Federici, 2004). Moreover, other
factors, such as the type, pathophysiology and genotype of
VWD, determine the response to desmopressin (Castaman
et al, 2008; Sharma & Flood, 2017). Therefore, severe VWD
type 1 and 2 patients without contra-indications for desmo-
pressin, should receive a test dose of desmopressin (03 lg/
kg intravenously) to evaluate whether they respond suffi-
ciently (Federici, 2008). In severe VWD patients who
respond well, treatment with desmopressin is often sufficient
to treat minor bleeding and to prevent bleeding during
minor surgery or interventions. In case of a life-threatening
bleeding or major surgery, VWF/FVIII concentrates are
needed. Moreover, repeated desmopressin use is limited by
tachyphylaxis and side-effects that may occur, including
hypotension and hyponatraemia (Svensson et al, 2014).
Plasma-derived factor VWF (/FVIII) concentrates
Plasma-derived factor concentrates are the treatment of
choice in patients with severe VWD, and in patients that do
not respond to desmopressin or in whom desmopressin is
contraindicated (Heijdra et al, 2017). VWF/FVIII concen-
trates are derived from plasma and are mostly purified by
heparin ligand chromatography or ion-exchange chromatog-
raphy (Peyvandi et al 2019a). Viral inactivation is mostly
performed with solvent detergent and dry heat to prevent
virus transfer (Heijdra et al, 2017). There are several brands
of plasma-derived VWF/FVIII concentrates available, with a
large variation in VWF:RCo/VWF:Ag ratio (from 029 to
24) and VWF:RCo/FVIII:C ratio (from 081 to >10) (Heij-
dra et al, 2017). Therefore, it is important to take into
account the exact VWF and FVIII values of a concentrate
(Castaman et al, 2013; Leebeek & Eikenboom, 2016).
Upon infusion of VWF and FVIII concentrates, 1 iu VWF:
RCo/kg increases VWF to around 15 iu/dl, whereas 1 iu
FVIII:C/kg increases plasma FVIII levels to around 2 iu/dl
(Heijdra et al, 2017). Based on this presumed in vivo recov-
ery, the VWF:RCo/FVIII:C ratio of the used product, and the
targeted VWF and FVIII levels, the dose of concentrate that
should be administered can be determined (Table I).
Factor concentrates can be administered by once or twice
daily bolus infusions, or by continuous infusion. During sur-
gery or repeated VWF/FVIII concentrate infusions, it is rec-
ommend to measure both VWF:RCo and FVIII:C daily to
ensure that the target levels of VWF and FVIII are reached
(Table I). Despite the fact that it is still disputed whether
normalisation of VWF, FVIII or both are needed to achieve
adequate haemostasis in VWD patients, we strive for normal-
isation of both factors during surgery or other interventions,
as is also suggested in most guidelines (Table I) (Castaman
et al, 2013; Laffan et al, 2014; Leebeek & Eikenboom, 2016;
Mannucci & Franchini, 2017). It has recently been shown
that current treatment strategies may lead to both under-
and overdosing (Hazendonk et al, 2018a), and may be caused
by pharmacokinetic and pharmacodynamic differences of
VWF and FVIII (Pipe et al, 2016).
An important physiological mechanism that should be
considered in treatment with VWF/FVIII concentrates is that
VWD patients have normal FVIII synthesis, but increased
FVIII proteolysis because of reduced FVIII binding to VWF,
resulting in low FVIII levels. In patients with severe VWD,
FVIII levels may be less than 10 iu/dl, thereby worsening the
bleeding phenotype and increasing the bleeding risk during
interventions (de Wee et al, 2012). Therefore, an increase of
both VWF and FVIII by infusion of VWF/FVIII concentrates
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is needed. However, increase of VWF levels after administra-
tion of concentrates will also lead to an increment of endoge-
nous FVIII, because of reduced FVIII proteolysis. This may
lead to high FVIII levels after several days of treatment with
VWF/FVIII concentrate (Mannucci, 2004). These high FVIII
levels may be associated with an increased risk of thrombosis,
especially after major surgery (Coppola et al, 2012). There-
fore, it is important to measure VWF and FVIII:C regularly
to assess the risk for developing thrombosis and to adjust
dosing.
Purified VWF plasma concentrates without FVIII are
available in some countries. Pure VWF concentrates increase
VWF levels immediately, whereas FVIII levels increase gradu-
ally over time. By binding of endogenous FVIII to the exoge-
nous VWF, FVIII is stabilised and FVIII degradation
prevented, thereby gradually increasing circulating FVIII
levels. Most patients reach FVIII levels of >60 iu/dl after a 6-
h infusion of pure VWF concentrate (Borel-Derlon et al,
2007). In case of planned surgery, the first dose of pure
VWF can be given the evening prior to surgery. Additional
FVIII should be co-administered if pure VWF concentrates
are administered in emergency situations, such as severe
bleeding or shortly before emergency surgery in patients with
severe VWD, in order to increase FVIII levels immediately
(Heijdra et al, 2017).
Recombinant VWF concentrate
Recombinant VWF (rVWF) concentrate (VEYVONDI,
Takeda Pharmaceutical Company Limited, Tokyo, Japan)
was registered in 2015 for on demand treatment of bleeding
in VWD patients (Turecek et al, 2009). Recombinant VWF is
synthesized from a Chinese Hamster Ovary (CHO) cell line
that co-expresses VWF and F8 genes. Subsequently, this is
purified by immune-affinity chromatography, which results
in a rVWF molecule with >99% purity (Peyvandi et al,
2019a). Thus, rVWF only contains VWF and does not con-
tain FVIII. Therefore, patients that are treated with rVWF in
acute situations may need additional FVIII infusion(s), as is
done when pure VWF plasma concentrates are used. rVWF
concentrate is not exposed to ADAMTS13 during the manu-
facturing process and therefore has more large, haemostatic
highly active VWF multimers. Furthermore, during treatment
with rVWF there is no risk of viral transmission and there
may be a lower chance of developing an allergic reaction
(Peyvandi et al, 2019a).
The first phase 3 trial in rVWF, in which it was com-
bined with rFVIII concentrate, showed that on-demand
rVWF treatment had an excellent haemostatic efficacy for
bleeding episodes in 969% of patients, whereas a good
haemostatic efficacy was reached in the remaining patients
(Gill et al, 2015). No thrombotic events or severe allergic
reactions occurred, suggesting that rVWF is safe to use. A
recent phase 3 trial investigating rVWF in 15 severe VWD
patients indicated that rVWF was also effective in patients
undergoing elective surgery (Peyvandi et al,). One patient
developed deep vein thrombosis, which could possibly be
treatment related. Both previous trials showed that rVWF
has good pharmacokinetic and pharmacodynamic proper-
ties. Due to stabilization of endogenous FVIII by rVWF
binding, nearly all VWD patients with mean baseline FVIII:
C levels of 16 iu/dl, achieved FVIII:C above 60 iu/dl at 6 h
post-rVWF-infusion (Gill et al, 2015; Peyvandi et al,
2019b). In two cases, FVIII was administered because FVIII:
C was <60 iu/dl. A recent review suggested that rVWF can
be administered as monotherapy, without FVIII concen-
trates, if an immediate rise in FVIII:C is not necessary,
FVIII:C levels are above 40 iu/dl or during elective surgeries
(Peyvandi et al, 2019a).
Two phase 3 trials are currently ongoing which investigate
the use of rVWF as long-term prophylaxis (NCT02973087)
to prevent bleeding episodes, and the use of rVWF concen-
trate in paediatric patients (NCT 02932618). In the coming
years it will become clear in which patients and in which set-
tings rVWF can be used for the prevention and treatment of
bleeding in VWD.
Table I. Use of factor concentrates in severe
VWD patients.
Indication
Dose*
(iu/kg)
Target levels of VWF:RCo and
FVIII:C (iu/dl)
Treatment duration
(days)Day 1 After day 1
Bleeding
Mild to moderate 20–40 Peak >50–80 Through >30 1–3
Severe 50 Peak >100 Through >50 3–10
Intervention
Dental extraction 25 Peak >50 1
Minor surgery 30–60 Peak >50–80 Through >30 1–5
Major surgery 50–60 Peak >100 Through >50 7–10
Delivery 40–50 Peak >100 Through >50 3–7†
*The concentrate dose depends on the type and brand of concentrate.
†Three to five days after vaginal labour, and 5–7 days after caesarean section, depending on
bleeding and factor levels.
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Supportive treatment of severe VWD
Besides increasing VWF and FVIII levels, VWD patients may
also benefit from supportive treatment. Given that the
haemostatic system is a balance between coagulation and fib-
rinolysis, inhibition of fibrinolysis may have a beneficial
effect in VWD patients, especially in the management of
mucocutanous bleeding. Furthermore, women with VWD
with menorrhagia may benefit from hormonal therapy.
Fibrinolysis inhibitors
Fibrinolysis inhibitors prevent fibrin degradation by inhibit-
ing the interaction between plasminogen and fibrin. The use
of these agents is recommended in case of mucocutaneous
bleeding, because of their high effectiveness in controlling
bleeds associated with mucosa, in which high fibrinolytic
activity is found (Sindet-Pedersen, 1991). In addition, they
have low costs and low risk of major side-effects. The effec-
tiveness of fibrinolysis inhibitors, such as tranexamic acid
and epsilon-aminocaproic acid, in patients with inherited
bleeding disorders undergoing oral or dental surgery has
recently been reviewed (van Galen et al, 2019). It was found
that only a limited number of studies have been performed
in haemophilia patients, whereas no studies were performed
in VWD. The performed studies revealed a beneficial effect
of systemically administered tranexamic acid and reduction
of post-operative bleeding (van Galen et al, 2019).
We prescribe tranexamic acid for (severe) VWD patients
with mucosal tissue-associated surgery, including tonsillec-
tomy, hysterectomy and gastro-intestinal surgery or with
mucocutaneous bleeding: 1000 mg four times a day (total
4000 mg daily) in adults and 25 mg/kg/day divided over 2–3
doses per day in children for 7 days. In patients undergoing
dental surgery we additionally prescribe mouth wash 4 times
daily with oral tranexamic solution.
Hormonal treatment
Menorrhagia is a major clinical problem in women with
VWD and is associated with a reduced quality of life (Kadir
et al, 1998; de Wee et al, 2012). About 80% of women with
VWD experience menorrhagia and need some kind of treat-
ment for their symptoms, in contrast to 5–10% of the gen-
eral population (de Wee et al, 2011b). Moreover,
hysterectomy is performed because of menorrhagia in 20%
of women with VWD, which is nearly twice as high com-
pared to the general population (de Wee et al, 2011b).
VWD women with menorrhagia should first be investi-
gated by a gynaecologist to exclude anatomical and hormonal
abnormalities. If no gynaecological abnormalities are found,
oral contraceptives containing progesterone and oestrogens
are recommended for menorrhagia treatment (Kadir et al,
1998). Women can choose to have a contraception-free week
or continuous treatment (without a week stop). Both
methods have been shown to be effective in decreasing bleed-
ing severity and bleeding days in healthy women (Kwiecien
et al, 2003). Tranexamic acid can also be used during the
menstrual period to decrease blood loss (Bonnar & Shep-
pard, 1996).
In case oral contraceptives are not effective or if women
do not want to use them, a levonorgestrel-containing
intrauterine device (IUD; Mirena) may be an alternative.
Adequate VWF and FVIII levels are required at the time of
IUD placement, by infusion of either desmopressin or VWF/
FVIII concentrates. If IUDs are not successful, desmopressin
or VWF concentrates may be necessary to prevent and treat
menorrhagia. This can be given prophylactically during the
first few days of menstruation, and results in reduced blood
loss in most women (Holm et al, 2015). If all these treatment
options are not successful, then endometrial ablation or hys-
terectomy may be considered (Rubin et al, 2004).
Platelet transfusion
VWD patients with intractable bleeding, despite infusion of
VWF/FVIII concentrate, can benefit from platelet transfusion
(Castillo et al, 1991). In contrast to platelets of VWD patients,
donor platelets contain functional VWF and may therefore
deliver VWF at the site of injury. Several case series have
shown that platelet transfusions can improve haemostasis and
may stop bleeding episodes in VWD patients (Fressinaud
et al, 1994; Castillo et al, 1997). Recent in vitro studies indi-
cated that platelets restore thrombin generation in VWD type
3 (Szanto et al, 2019). No clinical data are available yet to
indicate when platelet transfusions should be initiated in sev-
ere VWD patients with intractable bleeding. One should take
the severity and site of bleeding into account when consider-
ing initiation of platelet transfusions. In case of joint bleeds,
muscle bleeds, central nervous system bleeds or continuous
lowering of haemoglobin despite VWF/FVIII concentrates, one
should consider initiating platelet infusions.
Management in specific situations
Pregnancy and labour
For women with severe VWD, pregnancy and delivery carry
a potential risk for bleeding and should be carefully moni-
tored and managed (Fig 1). In the general population VWF
and FVIII levels increase during pregnancy, especially in the
third trimester. A similar increase is seen in mild type 1
VWD patients. At the time of labour, FVIII and VWF levels
can be two to three times higher compared to baseline levels,
and may thereby normalise (Sood et al, 2016). Therefore,
VWF and FVIII levels should be measured at least once in
the third trimester to be able to determine a treatment plan
for delivery (Fig 1). After delivery, VWF and FVIII levels
decrease to baseline levels within 3 weeks postpartum (James
et al, 2015). In type 2 VWD, VWF:Ag and FVIII:C levels also
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increase during pregnancy, but VWF:RCo remains low (Cas-
taman & James, 2019). Therefore, the increase of dysfunc-
tional VWF protein may not normalise haemostasis in these
women. In women with VWD type 3 no VWF is detectable
and FVIII levels remain low during pregnancy, making them
most prone to post-partum haemorrhage (PPH).
During delivery, complications may not only concern the
mother with VWD, but also the potentially affected child.
Therefore, it is of utmost importance to follow a multidisci-
plinary approach (Fig 1). The monitoring and care of preg-
nant women with VWD should only be undertaken in
hospitals that have experience with patients with bleeding
disorders. Furthermore, a multidisciplinary team of (at least)
a haematologist, paediatric haematologist, gynaecologist and
anaesthesiologist with expertise in bleeding disorders should
formulate a management plan for care during pregnancy and
at the time of delivery (Fig 1).
Both the bleeding risk for the pregnant patient and the pos-
sibility of bleeding in an affected child have to be considered.
In many patients with type 2, in whom the causative VWF
mutation is known, we discuss with the patient and her part-
ner the possibility of performing amniotic fluid aspiration at
32–24 weeks of pregnancy to establish or exclude the diagnosis
of VWF in the child. The causative mutation should be known
preferably before pregnancy. In case the child is affected by
severe VWD, atraumatic labour should be advised. This is also
advised in case no prenatal diagnostics have been performed
or are inconclusive (Fig 1). In women with type 3 VWD caused
by a double heterozygote mutation, this is generally not neces-
sary, because the child will probably not be severely affected,
although this may depend on the underlying mutations (Cas-
taman et al, 2006; Peake & Goodeve, 2010).
Although several studies have been performed on postpar-
tum haemorrhage in VWD patients, the quality of those
observational studies is low (Kadir & Chi, 2006; James et al,
2015; Stoof et al, 2015). It is generally accepted that no treat-
ment is necessary if the levels of VWF and FVIII are >50 iu/
dl during third trimester. Desmopressin can be administered
in women with type 1 VWD that are known to have a good
desmopressin response (Nichols et al, 2008; Laffan et al,
2014). We only administer desmopressin after clamping the
umbilical cord in order to prevent severe hypotension in the
mother, which can harm the unborn child. There is still lim-
ited evidence for treatment recommendations using FVIII/
VWF concentrates in pregnant VWD patients. In an observa-
tional study, James et al (2015) found no incidence of PPH
in 17 type 1 VWD patients with VWF and FVIII levels
>50 iu/dl during third trimester, who did not receive pro-
phylactic treatment. In 15 women (7 with type 1 and 8 with
type 2) with mean VWF:RCo of 34 (0–75) iu/dl during third
trimester that were prophylactically treated with factor con-
centrate during labour, only one patient with type 2B VWD
had excessive bleeding (James et al, 2015). VWD women who
were prophylactically treated with factor concentrates had,
despite treatment, more blood loss compared to women with-
out VWD and untreated type 1 VWD women (James et al,
2015). Stoof et al (2015) observed PPH in over 50% of type 1
and type 2 VWD patients with VWF levels <50 iu/dl in the
third trimester, despite VWF concentrate treatment aiming
target levels of 100 iu/dl at labour. Based on these findings,
they suggested that higher (more physiological) levels of 150–
200 iu/dl, should be the target at the time of delivery. Current
treatment guidelines may not be sufficient to prevent PPH in
these women, and new treatment approaches aiming for higher
VWF and FVIII levels may be needed to prevent PPH in this
group (Ragni et al, 2017).
Thrombocytopenia may occur during pregnancy in
women with type 2B VWD. It is recommended that platelet
counts should be monitored regularly in the third trimester.
In cases where platelet counts at delivery are <50 9 109/l,
Before delivery During delivery After delivery
•Reference to a haemophilia
treatment centre
•Multidisciplinary approach1
•Measure VWF and FVIII
levels in third trimester
•Formulate management plan for 
delivery
•Consider amniotic fluid sampling
to diagnose or exclude VWD in
the unborn child2
•VWF/FVIII concentrates readily
available in delivery room
•Administer VWF/FVIII concentrates to women
with VWF:RCo and FVIII:C <50 iu/dl
•Neuraxial anaesthesia can only be performed if
VWF and FVIII levels have been normalised3
Vaginal
•Therapy
of choice
Caesarean section
•Fetal need/
obstetric causes
Atraumatic delivery4
•Child with VWD
•No prenatal diagnostic
test performed
VWF/FVIII concentrates:
•continue 3–7 days
Tranexamic acid:
•4 times daily 1000 mg,
7–14 days
•An increased risk of
post-partum bleeding,
despite normalisation of
VWF and FVIII levels
Delivery
Fig 1. Management of delivery in severe VWD patients. 1Consists of a haematologist, clinical geneticist, gynaecologist, paediatric haematologist
and anaesthesiologist. 2If the causative VWF gene mutation is known in the mother. 3Either physiologically or by factor infusion or desmopressin.
4No invasive management with vacuum or forceps.
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platelet transfusion is recommended with a target level
>50 9 109/l (Kruse-Jarres & Johnsen, 2018).
Neuraxial anaesthesia can only be performed if VWF and
FVIII levels have been normalised. If levels have not been
normalised at the time of labour, and neuraxial anaesthesia
is preferred, prophylactic factor infusion or desmopressin
should be given to ensure normal VWF and FVIII levels at
the time of performing neuraxial anaesthesia (Nichols et al,
2008). However, it should be noted that some guidelines rec-
ommended against neuraxial anaesthesia in patients with
type 2 or 3 VWD (Laffan et al, 2014).
For women with severe VWD, we infuse FVIII/VWF at a
concentrate dosage of 40–60 VWF:RCo iu/kg at start of
labour, continued twice daily 25 iu/kg for 3–5 days for vagi-
nal labour, and 5–7 days after caesarean section, depending
on bleeding and factor levels (Table I). In addition, all
women with VWD should, independent of their VWD sever-
ity and VWF levels, receive tranexamic acid peri- and at least
for 7 days postpartum (Fig 1). Tranexamic acid lowers the
risk of secondary post-partum haemorrhage and is safe for
pregnant women and for their child during lactation (Hawke
et al, 2016).
Surgery and dental interventions
In patients undergoing surgery, the goal is to increase VWF
and FVIII levels sufficiently to prevent bleeding. For major
surgery, peak VWF and FVIII levels should be at least 100
iu/dl on day 1, to establish normal haemostasis (Table I). In
severe VWD patients, this can be achieved by infusion of
plasma-derived FVIII/VWF concentrate, pure VWF concen-
trate or rVWF. VWF concentrates should be administered at
a loading dose of 50–60 VWF:RCo iu/kg in major surgery,
followed by half of the dosage for maintenance every 8–24 h
for major surgery and every 12–48 h for minor surgery (Cas-
taman et al, 2013; Laffan et al, 2014; Leebeek & Eikenboom,
2016). After major surgery, trough levels should be at least
50 iu/dl for 7–10 days (Table I). For minor surgery one can
aim for peak target FVIII and VWF levels of 50–80 iu/dl on
day 1 followed by trough levels of at least 30 iu/dl for 1–
5 days, depending on the type of surgery. In patients under-
going dental extraction, peak target levels of at least 50 iu/dl
on day 1 are sufficient to prevent bleeding. Moreover, local
measures, including secure suturing, wound compression and
good wound sealing are, in addition to fibrinolysis inhibitors,
important to prevent re-bleeding.
Treatment of gastrointestinal bleeding
Gastrointestinal bleeding is quite common and can be life
threatening in severe VWD patients. In general, the preva-
lence of gastrointestinal bleeding is about 15% in VWD
patients, but in patients with type 2 and type 3 VWD the
prevalence is up to 27% (de Wee et al, 2012). Previous stud-
ies have shown that gastrointestinal bleeding almost
exclusively occurs in patients that have a reduction of HMW
VWF multimers, which is the case in type 2A, type 2B and
type 3 VWD (Leebeek & Eikenboom, 2016). Gastrointestinal
bleeding is more common in young, black or male VWD
patients (Tsagianni et al, 2019). The most significant predic-
tors of bleeding include angiodysplasia, diverticulitis, hepati-
tis C and smoking (Tsagianni et al, 2019).
VWD patients with gastrointestinal bleeding should be
treated immediately with VWF/FVIII concentrates. In addi-
tion, endoscopic management is needed to be able to treat
local sites of bleeding. Many VWD patients have recurrent
gastrointestinal bleeding, despite treatment with factor con-
centrates. This may be caused by angiodysplasia or vascular
malformations in the intestines, which give a higher chance
for continuation of bleeding or re-bleeding (Makris et al,
2015; Tsagianni et al, 2019). Many drugs have been used to
treat VWD patients with persistent gastrointestinal bleeding.
The effectiveness of octreotide and thalidomide has been
shown in the treatment of angiodysplasia-related gastroin-
testinal bleeding in the general population (Iannone et al,
2016). For VWD patients, this has only been reported in
small case series (Bowers et al, 2000; Engelen et al, 2015).
Statins, which have anti-angiogenetic properties, have also
been reported to reduce bleeding in intractable gastrointesti-
nal bleeding in VWD patients (Sohal & Laffan, 2008; Alikhan
& Keeling, 2010). The use of lenalidomide as treatment for
angiodysplasia-related gastro intestinal bleeding in VWD was
recently reported to be successful in increasing bleed-free
duration (Khatri et al, 2018). It was also recently shown in
one case with type 2A VWD that rVWF, containing high
content of HMW multimers, was effective in the treatment
of severe gastrointestinal bleeding that was unresponsive to
other standard treatments for VWD (Brown, 2017). It is
noteworthy that the previously mentioned case reports may
be subjected to publication bias, and therefore well-designed
studies are needed to assess the efficacy and side-effects of
these drugs for the treatment of gastrointestinal bleeding in
VWD patients.
In our centre, we only use thalidomide and statins in
patient with recurrent gastrointestinal bleeding despite local
measures and on-demand infusion of FVIII/VWF concen-
trates. If bleeding persists we initiate long-term prophylaxis
with FVIII/VWF concentrate (Saccullo & Makris, 2016).
Patients with alloantibodies to VWF
A rare but severe side effect of treatment with plasma-
derived factor concentrates is development of alloantibodies
against VWF. Alloantibodies against VWF form in response
to treatment with plasma-derived VWF factor -containing
concentrates, and are mostly polyclonal IgG antibodies
(James et al, 2013). The first results of the 3WINTER-IPS
project, which included a large cohort of 260 type 3 VWD
patients, showed that a 6% prevalence of alloantibodies in
type 3 VWD patients (Stufano et al, 2019). Recently the first
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type 2B VWD patient with alloantibodies was reported (Baaij
et al, 2015). Patients with alloantibodies against VWF gener-
ally have a limited recovery and a rapid clearance of VWF
after infusion of VWF concentrates (James et al, 2013; Fran-
chini & Mannucci, 2018). Alloantibodies may also lead to
immune complex formation and, subsequently, complement
activation, causing life-threatening anaphylactic allergic reac-
tions (Bergamaschini et al, 1995; Franchini et al, 2009; James
et al, 2013; Franchini & Mannucci, 2018). Therefore, VWF-
containing concentrates are contraindicated in patients with
alloantibodies against VWF.
Several treatment options have been reported for the treat-
ment of severe VWD patients with alloantibodies (Scott et al,
2018). Continuous infusion of high dose FVIII concentrates
can be a treatment option, however high dosages of FVIII are
needed because FVIII has a very short half-life in these patients
(Mannucci & Federici, 1995). Moreover, this may be con-
traindicated in patients with high titre VWF alloantibodies,
because it was shown that it can precipitate anaphylactic reac-
tions (Mannucci et al, 1981). In patients that do not have
high-titre alloantibodies and that do not have an allergic reac-
tion to VWF, a high-dose of VWF/FVIII concentrate may also
be successful (Martin-Salces et al, 2012). Furthermore, there is
limited evidence to treat patients with alloantibodies to VWF
with recombinant activated FVII (rFVIIa; Novoseven) or
FVIII inhibitor bypassing activity (FEIBA) (Grossmann et al,
2000; Boyer-Neumann et al, 2003), although one of the rare
cases that was treated with rFVIIa developed venous throm-
boembolism (Boyer-Neumann et al, 2003).
Long-term prophylactic treatment
Prophylactic treatment with regular infusions of factor con-
centrate is currently the standard of care for patients with
severe haemophilia A and B, but this is not the case in
patients with severe VWD. Despite the fact that patients with
severe VWD may have recurrent bleeds, including joint
bleeds, gastrointestinal bleeds, severe nose bleeds and menor-
rhagia, only a few studies on the use of prophylaxis have
been reported (Berntorp & Petrini, 2005; Abshire et al,
2015). In Sweden, prophylaxis has been given to children
and adults with severe VWD for many decades, mainly in
children with severe nose bleeds and adults with joints bleeds
(Berntorp & Petrini, 2005). In an international survey by the
VWD Prophylaxis Network covering 5300 VWD patients, 99
patients had received prophylaxis, predominantly for joint
bleeding (41%), oral/nasal bleeding (24%) and gastro-intesti-
nal bleeding (12%) (Berntorp & Abshire 2006). Prophylaxis
was given to 24% of patients with type 3, 18% with type 2
and only 02% with type 1.
The first prospective study on prophylaxis with VWF/FVIII
concentrate in 12 severe VWD patients showed that a dose of
50 VWF:RCo iu/kg two or three times per week substantially
reduced the number of mucosal and joint bleeding episodes
(Abshire et al, 2015). The data from this prospective study
were analysed together with a retrospective study and revealed
significant reduction of bleeding rates for epistaxis, gastroin-
testinal bleeding, joint bleeding and menorrhagia. Patients
with gastrointestinal bleeding needed three or more times per
week prophylaxis, as well as higher dosages (Holm et al, 2015).
Recently a prospective randomised Italian study was reported
on the use of prophylaxis versus on-demand treatment in 19
patients with severe VWD. This phase 3 study also showed a
reduction of the number of bleeding events, although it had a
small sample size and strong heterogeneity in the study popu-
lation (Peyvandi et al, 2019c). A prospective phase 3 trial is
ongoing to investigate the efficacy and safety of prophylactic
use of recombinant VWF concentrate in patients with severe
VWD (NCT02973087).
Currently, we initiate prophylactic treatment with FVIII/
VWF concentrates only in severe VWD patients that have
repeated bleeding episodes, mostly concerning joint bleeding
and gastro-intestinal bleeding. Also, in patients with severe
menorrhagia that do not respond to other treatment, such as
oral contraceptives, intrauterine device and tranexamic acid,
we initiate prophylactic VWF/FVIII concentrate during the
menstrual period. Before starting prophylaxis, patients
receive instructions for home treatment and self-infusion of
the coagulation factor concentrate. Prophylaxis is initiated
with twice a week 50 VWF:RCo iu/kg intravenously and the
dose is increased to three times a week if bleeding persists.
The benefit and burden of prophylaxis is evaluated with the
patients at least twice-yearly to discuss continuing or stop-
ping prophylaxis. Most patients are reluctant to discontinue
treatment, especially in those with gastrointestinal bleeding,
because of the observed benefit of prophylaxis (Saccullo &
Makris, 2016).
Future developments in the treatment of
severe VWD patients
Individualized treatment based on pharmacokinetic
modelling
Recently we have shown that the current dosing of FVIII/
VWF concentrate for surgical procedures based on body
weight results in an overdosing in most patients with VWD
(Hazendonk et al, 2018a). This suggest that individualised
dosing based on a pharmacokinetic study of each patient
planned for surgery may result in better outcome and may
be more cost-effective (Berntorp, 2018, Hazendonk et al,
2018a). Only limited studies have been performed so far on
the use of pharmacokinetic-based dosing in VWD (Lethagen
et al, 2007; Di Paola et al, 2011). These studies revealed that
pharmacokinetic analysis pre-surgery was of limited value.
Therefore better models should be developed based on both
FVIII:C and VWF:RCo levels to improve accuracy of predic-
tion, as is now also employed in haemophilia (Hazendonk
et al, 2018b). We are currently performing a trial investigat-
ing the individualized treatment of VWD patients based on
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population pharmacokinetic models. In this trial, we calcu-
late the optimum required dosages of desmopressin and
VWF/FVIII concentrates based on VWF and FVIII measure-
ments at baseline, 4, 24 and 48 h after administration of
desmopressin or VWF/FVIII concentrates. Using population
models, one can predict the dose needed by a patient to
reach the required target levels, reducing sub- and suprather-
apeutical VWF and FVIII levels.
Gene therapy
Gene therapy has only been investigated in a preclinical set-
ting for VWD (De Meyer et al, 2008; Wang et al, 2012; Por-
tier et al, 2018). In patients with haemophilia, gene therapy
has shown very good results in clinical trials (Perrin et al,
2019a). Compared to haemophilia, gene therapy for VWD
seems more challenging, mainly because of the large size of
the VWF gene, which makes it difficult to insert VWF cDNA
in viral gene transfer vectors. In addition, VWF is synthesized
mainly in the endothelium, which is difficult to target with
gene therapy. So far, VWF liver-specific gene transfer has
been used in mice models leading to higher plasma VWF
levels (Wang et al, 2012; Portier et al, 2018). More preclinical
studies are needed before gene therapy can be used in clinical
trials in patients suffering from severe VWD.
Conclusion
Management of severe VWD patients is more demanding
than management of mild VWD/ type 1 patients. Severe
VWD patients carry a high risk of bleeding in some specific
situations, such as during delivery or surgery and after devel-
opment of alloantibodies to VWF. Patients with severe VWD
who lack HMW multimers also have a high risk of recurrent
gastrointestinal bleeding due to angiodysplasia. Patients suf-
fering from recurrent bleedings may benefit from prophy-
laxis, which is only offered to a small number of patients.
Future prospective studies are needed to investigate the bene-
fit of newer treatment options, to improve current manage-
ment and update guidelines in these patients.
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